Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain

Zhoumou Chen, Timothy M. Doyle, Livio Luongo, Tally M. Largent-Milnes, Luigino Antonio Giancotti, Grant Kolar, Silvia Squillace, Serena Boccella, John K. Walker, Alexander Pendleton, Sarah Spiegel, William L. Neumann, Todd W Vanderah, Daniela Salvemini

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Neuropathic pain afflicts millions of individuals and represents a major health problem for which there is limited effective and safe therapy. Emerging literature links altered sphingolipid metabolism to nociceptive processing. However, the neuropharmacology of sphingolipid signaling in the central nervous system in the context of chronic pain remains largely unexplored and controversial. We now provide evidence that sphingosine-1-phosphate (S1P) generated in the dorsal horn of the spinal cord in response to nerve injury drives neuropathic pain by selectively activating the S1P receptor subtype 1 (S1PR1) in astrocytes. Accordingly, genetic and pharmacological inhibition of S1PR1 with multiple antagonists in distinct chemical classes, but not agonists, attenuated and even reversed neuropathic pain in rodents of both sexes and in two models of traumatic nerve injury. These S1PR1 antagonists retained their ability to inhibit neuropathic pain during sustained drug administration, and their effects were independent of endogenous opioid circuits. Moreover, mice with astrocyte-specific knockout of S1pr1 did not develop neuropathic pain following nerve injury, thereby identifying astrocytes as the primary cellular substrate of S1PR1 activity. On a molecular level, the beneficial reductions in neuropathic pain resulting from S1PR1 inhibition were driven by interleukin 10 (IL-10), a potent neuroprotective and anti-inflammatory cytokine. Collectively, our results provide fundamental neurobiological insights that identify the cellular and molecular mechanisms engaged by the S1PR1 axis in neuropathic pain and establish S1PR1 as a target for therapeutic intervention with S1PR1 antagonists as a class of nonnarcotic analgesics.

Original languageEnglish (US)
Pages (from-to)10557-10562
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume116
Issue number21
DOIs
StatePublished - Jan 1 2019

Fingerprint

Lysosphingolipid Receptors
Neuralgia
Astrocytes
Sphingolipids
Wounds and Injuries
Neuropharmacology
Non-Narcotic Analgesics
Chronic Pain
Interleukin-10
Opioid Analgesics
Rodentia
Anti-Inflammatory Agents
Central Nervous System
Pharmacology
Cytokines

Keywords

  • Astrocytes
  • Interleukin 10
  • S1P receptor subtype 1
  • Sphingosine-1-phosphate
  • Traumatic nerve injury-induced neuropathic pain

ASJC Scopus subject areas

  • General

Cite this

Chen, Z., Doyle, T. M., Luongo, L., Largent-Milnes, T. M., Giancotti, L. A., Kolar, G., ... Salvemini, D. (2019). Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain. Proceedings of the National Academy of Sciences of the United States of America, 116(21), 10557-10562. https://doi.org/10.1073/pnas.1820466116

Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain. / Chen, Zhoumou; Doyle, Timothy M.; Luongo, Livio; Largent-Milnes, Tally M.; Giancotti, Luigino Antonio; Kolar, Grant; Squillace, Silvia; Boccella, Serena; Walker, John K.; Pendleton, Alexander; Spiegel, Sarah; Neumann, William L.; Vanderah, Todd W; Salvemini, Daniela.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, No. 21, 01.01.2019, p. 10557-10562.

Research output: Contribution to journalArticle

Chen, Z, Doyle, TM, Luongo, L, Largent-Milnes, TM, Giancotti, LA, Kolar, G, Squillace, S, Boccella, S, Walker, JK, Pendleton, A, Spiegel, S, Neumann, WL, Vanderah, TW & Salvemini, D 2019, 'Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain', Proceedings of the National Academy of Sciences of the United States of America, vol. 116, no. 21, pp. 10557-10562. https://doi.org/10.1073/pnas.1820466116
Chen, Zhoumou ; Doyle, Timothy M. ; Luongo, Livio ; Largent-Milnes, Tally M. ; Giancotti, Luigino Antonio ; Kolar, Grant ; Squillace, Silvia ; Boccella, Serena ; Walker, John K. ; Pendleton, Alexander ; Spiegel, Sarah ; Neumann, William L. ; Vanderah, Todd W ; Salvemini, Daniela. / Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain. In: Proceedings of the National Academy of Sciences of the United States of America. 2019 ; Vol. 116, No. 21. pp. 10557-10562.
@article{f9c61521a0d34fbb8db2be076fb6a3da,
title = "Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain",
abstract = "Neuropathic pain afflicts millions of individuals and represents a major health problem for which there is limited effective and safe therapy. Emerging literature links altered sphingolipid metabolism to nociceptive processing. However, the neuropharmacology of sphingolipid signaling in the central nervous system in the context of chronic pain remains largely unexplored and controversial. We now provide evidence that sphingosine-1-phosphate (S1P) generated in the dorsal horn of the spinal cord in response to nerve injury drives neuropathic pain by selectively activating the S1P receptor subtype 1 (S1PR1) in astrocytes. Accordingly, genetic and pharmacological inhibition of S1PR1 with multiple antagonists in distinct chemical classes, but not agonists, attenuated and even reversed neuropathic pain in rodents of both sexes and in two models of traumatic nerve injury. These S1PR1 antagonists retained their ability to inhibit neuropathic pain during sustained drug administration, and their effects were independent of endogenous opioid circuits. Moreover, mice with astrocyte-specific knockout of S1pr1 did not develop neuropathic pain following nerve injury, thereby identifying astrocytes as the primary cellular substrate of S1PR1 activity. On a molecular level, the beneficial reductions in neuropathic pain resulting from S1PR1 inhibition were driven by interleukin 10 (IL-10), a potent neuroprotective and anti-inflammatory cytokine. Collectively, our results provide fundamental neurobiological insights that identify the cellular and molecular mechanisms engaged by the S1PR1 axis in neuropathic pain and establish S1PR1 as a target for therapeutic intervention with S1PR1 antagonists as a class of nonnarcotic analgesics.",
keywords = "Astrocytes, Interleukin 10, S1P receptor subtype 1, Sphingosine-1-phosphate, Traumatic nerve injury-induced neuropathic pain",
author = "Zhoumou Chen and Doyle, {Timothy M.} and Livio Luongo and Largent-Milnes, {Tally M.} and Giancotti, {Luigino Antonio} and Grant Kolar and Silvia Squillace and Serena Boccella and Walker, {John K.} and Alexander Pendleton and Sarah Spiegel and Neumann, {William L.} and Vanderah, {Todd W} and Daniela Salvemini",
year = "2019",
month = "1",
day = "1",
doi = "10.1073/pnas.1820466116",
language = "English (US)",
volume = "116",
pages = "10557--10562",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "21",

}

TY - JOUR

T1 - Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain

AU - Chen, Zhoumou

AU - Doyle, Timothy M.

AU - Luongo, Livio

AU - Largent-Milnes, Tally M.

AU - Giancotti, Luigino Antonio

AU - Kolar, Grant

AU - Squillace, Silvia

AU - Boccella, Serena

AU - Walker, John K.

AU - Pendleton, Alexander

AU - Spiegel, Sarah

AU - Neumann, William L.

AU - Vanderah, Todd W

AU - Salvemini, Daniela

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Neuropathic pain afflicts millions of individuals and represents a major health problem for which there is limited effective and safe therapy. Emerging literature links altered sphingolipid metabolism to nociceptive processing. However, the neuropharmacology of sphingolipid signaling in the central nervous system in the context of chronic pain remains largely unexplored and controversial. We now provide evidence that sphingosine-1-phosphate (S1P) generated in the dorsal horn of the spinal cord in response to nerve injury drives neuropathic pain by selectively activating the S1P receptor subtype 1 (S1PR1) in astrocytes. Accordingly, genetic and pharmacological inhibition of S1PR1 with multiple antagonists in distinct chemical classes, but not agonists, attenuated and even reversed neuropathic pain in rodents of both sexes and in two models of traumatic nerve injury. These S1PR1 antagonists retained their ability to inhibit neuropathic pain during sustained drug administration, and their effects were independent of endogenous opioid circuits. Moreover, mice with astrocyte-specific knockout of S1pr1 did not develop neuropathic pain following nerve injury, thereby identifying astrocytes as the primary cellular substrate of S1PR1 activity. On a molecular level, the beneficial reductions in neuropathic pain resulting from S1PR1 inhibition were driven by interleukin 10 (IL-10), a potent neuroprotective and anti-inflammatory cytokine. Collectively, our results provide fundamental neurobiological insights that identify the cellular and molecular mechanisms engaged by the S1PR1 axis in neuropathic pain and establish S1PR1 as a target for therapeutic intervention with S1PR1 antagonists as a class of nonnarcotic analgesics.

AB - Neuropathic pain afflicts millions of individuals and represents a major health problem for which there is limited effective and safe therapy. Emerging literature links altered sphingolipid metabolism to nociceptive processing. However, the neuropharmacology of sphingolipid signaling in the central nervous system in the context of chronic pain remains largely unexplored and controversial. We now provide evidence that sphingosine-1-phosphate (S1P) generated in the dorsal horn of the spinal cord in response to nerve injury drives neuropathic pain by selectively activating the S1P receptor subtype 1 (S1PR1) in astrocytes. Accordingly, genetic and pharmacological inhibition of S1PR1 with multiple antagonists in distinct chemical classes, but not agonists, attenuated and even reversed neuropathic pain in rodents of both sexes and in two models of traumatic nerve injury. These S1PR1 antagonists retained their ability to inhibit neuropathic pain during sustained drug administration, and their effects were independent of endogenous opioid circuits. Moreover, mice with astrocyte-specific knockout of S1pr1 did not develop neuropathic pain following nerve injury, thereby identifying astrocytes as the primary cellular substrate of S1PR1 activity. On a molecular level, the beneficial reductions in neuropathic pain resulting from S1PR1 inhibition were driven by interleukin 10 (IL-10), a potent neuroprotective and anti-inflammatory cytokine. Collectively, our results provide fundamental neurobiological insights that identify the cellular and molecular mechanisms engaged by the S1PR1 axis in neuropathic pain and establish S1PR1 as a target for therapeutic intervention with S1PR1 antagonists as a class of nonnarcotic analgesics.

KW - Astrocytes

KW - Interleukin 10

KW - S1P receptor subtype 1

KW - Sphingosine-1-phosphate

KW - Traumatic nerve injury-induced neuropathic pain

UR - http://www.scopus.com/inward/record.url?scp=85066099577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066099577&partnerID=8YFLogxK

U2 - 10.1073/pnas.1820466116

DO - 10.1073/pnas.1820466116

M3 - Article

C2 - 31068460

AN - SCOPUS:85066099577

VL - 116

SP - 10557

EP - 10562

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 21

ER -